Vir Biotechnology (VIR) “announced that the European Medicines Agency Committee for Orphan Medicinal Products, has issued a positive opinion on the application for orphan drug designation of tobevibart and elebsiran for the treatment of chronic hepatitis delta. This opinion is based on encouraging preliminary data from the Phase 2 SOLSTICE trial. Vir Biotechnology will present 24-week data from the Phase 2 SOLSTICE trial at AASLD The Liver Meeting(R) in San Diego, CA, on November 18 at 6.15 p.m. PT. An investor conference call is scheduled for November 19, 2024, at 5.15 a.m. PT / 8.15 a.m. ET. CHD is a severe, progressive liver disease caused by the hepatitis delta virus (HDV)1. It is considered the most aggressive form of chronic viral hepatitis, with patients often progressing to cirrhosis and liver failure within 5 years of infection. Currently, there is no approved treatment in the United States, and treatment options are limited in the European Union and globally.”
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VIR:
- Vir Biotechnology reports ‘positive’ end-of-treatment data from MARCH study
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Vir Biotechnology participates in a conference call with JPMorgan
- Biotech Alert: Searches spiking for these stocks today
- Vir Biotechnology price target lowered to $26 from $28 at Barclays
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
